ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

174
Analysis
Health Care • South Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
bullish•Krafton
•16 Jun 2021 08:43

Krafton IPO Preview

According to the bankers' valuation, the expected market cap of Krafton is expected to be from 23.7 trillion won to 28.8 trillion won.

Logo
527 Views
Share
•22 May 2021 14:54

KOSPI 200 Rebalancing: Constituents with a ±5%pt Free Float Change

This post looks into KOSPI 200 constituents with a potential ±5%pt free float change in the upcoming rebalancing. It then examines the extent of...

Logo
519 Views
Share
•16 May 2021 16:36

Earnings Surprise KOSPI Stocks Potentially Hedging Against Inflation for Basket & Pairs Trades

This post finds the first-quarter earnings surprise stocks in KOSPI that potentially hedge against inflation for basket and pairs trades.

Logo
391 Views
Share
bullish•SK Bioscience
•19 Apr 2021 05:15

SK BioS Lockup Release Today: FO Drop Can Signal a Tight Supply for Passive Mirroring K200

SK Bioscience's lockup releases hit the market today. A substantial drop in FO can signal a tighter supply for passive funds, increasing the...

Logo
391 Views
Share
bullish•SK Bioscience
•13 Apr 2021 13:44

SK Bioscience K200 Entry: Potential Trades Reflecting SK Biopharm's Passive Inflow Pattern

This post finds the similarities between SK Biopharm and SK Bioscience concerning the passive money inflow pattern for the KOSPI 200 fast entry.

Logo
371 Views
Share
x